医学
蒂米
内科学
心脏病学
心肌梗塞
经皮冠状动脉介入治疗
溶栓
优势比
中性粒细胞与淋巴细胞比率
置信区间
ST段
淋巴细胞
作者
Çağrı Yayla,Mehmet Kadri Akboğa,Uğur Canpolat,Ahmet Akyel,Kadriye Gayretli̇ Yayla,Mehmet Doğan,Ekrem Yeter,Sinan Aydoğdu
出处
期刊:Angiology
[SAGE]
日期:2015-02-24
卷期号:66 (9): 831-836
被引量:39
标识
DOI:10.1177/0003319715573658
摘要
Patency of infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (pPCI) is associated with lower mortality and better clinical outcome. However, there were little data regarding the predictors of IRA patency before pPCI in the setting of STEMI. We aimed to assess the association of platelet to lymphocyte ratio (PLR) with IRA patency in STEMI. A total of 452 patients were enrolled and categorized as occluded or patent IRA. Patency IRA was assessed by the thrombolysis in myocardial infarction (TIMI) flow grade. Blood samples were obtained on admission to calculate PLR. Of all patients, 92 (20.4%) patients revealed pre-pPCI TIMI 3 flow in IRA. The PLR was significantly higher in occluded IRA group (138.4 ± 51.4 vs 95.4 ± 43.5, P < .001). Glucose, troponin I, and neutrophil to lymphocyte ratio (NLR) levels were also higher in occluded IRA group ( P < .05). Multivariate regression analysis demonstrated the PLR (odds ratio [OR]: 0.987; 95% confidence interval [CI]: 0.978-0.995, P = .002) and NLR (OR: 0.758; 95% CI: 0.584-0.985, P = .038) on admission as independent predictors of IRA patency. In conclusion, a higher PLR is a powerful and independent predictor of IRA patency in patients with STEMI before pPCI.
科研通智能强力驱动
Strongly Powered by AbleSci AI